PT  - JOURNAL ARTICLE
AU  - TATSUYA ITO
AU  - ISAKU OKAMOTO
AU  - KUNIHIKO TOKASHIKI
AU  - HIROKI SATO
AU  - TAKURO OKADA
AU  - GAI YAMASHITA
AU  - TOSHITAKA NAGAO
AU  - HIDEAKI HIRAI
AU  - NATSUKI SAIGUSA
AU  - KIYOAKI TSUKAHARA
TI  - PD-L1 Expression and Survival Rates Using TPS and CPS for Nivolumab-treated Head-and-Neck Cancer
AID  - 10.21873/anticanres.15628
DP  - 2022 Mar 01
TA  - Anticancer Research
PG  - 1547--1554
VI  - 42
IP  - 3
4099  - http://ar.iiarjournals.org/content/42/3/1547.short
4100  - http://ar.iiarjournals.org/content/42/3/1547.full
SO  - Anticancer Res2022 Mar 01; 42
AB  - Background/Aim: This study investigated the expression and survival rates of programmed cell death ligand 1 using the tumor proportion score (TPS)and combined positive score (CPS) for recurrent/metastatic head and neck cancer administered nivolumab. Patients and Methods: Forty-seven patients with recurrent/metastatic head and neck cancer with a history of platinum-based chemotherapy who received nivolumab between June 1st, 2017, and January 31st, 2019 were included in this study. Results: TPS and CPS were strongly correlated (r=0.546). When the TPS was high (≥40%), overall and progression-free survival were significantly better. The median overall survival was 8.5 months, median progression-free survival was not reached, and the 1-year progression-free survival rate was 71.4%. However, there was no significant difference in overall and progression-free survival between the groups with high CPS (≥20). Conclusion: This is the first report to show a strong correlation between TPS and CPS. High TPS (40% or higher) may be used as a predictor of prognosis and efficacy. Further studies are warranted to determine the use of the CPS as a biomarker.